中国骨质疏松杂志2024,Vol.30Issue(3) :405-412.DOI:10.3969/j.issn.1006-7108.2024.03.017

中医药调控PPARγ防治骨质疏松症的研究进展

Research progress of prevention and treatment of osteoporosis by traditional Chinese medicine based on PPARγ

吴雪 张惜燕 胡勇
中国骨质疏松杂志2024,Vol.30Issue(3) :405-412.DOI:10.3969/j.issn.1006-7108.2024.03.017

中医药调控PPARγ防治骨质疏松症的研究进展

Research progress of prevention and treatment of osteoporosis by traditional Chinese medicine based on PPARγ

吴雪 1张惜燕 1胡勇1
扫码查看

作者信息

  • 1. 陕西中医药大学,陕西咸阳 712046
  • 折叠

摘要

骨质疏松症是一种由于骨形成与骨吸收偶联失衡所引起的退行性疾病.过氧化物酶体增殖物激活受体γ(peroxisome proliferation-activated receptors γ,PPARγ)通过调控 Wnt/β-catenin、CEBPα、OPG/RANKL/RANK 信号通路加快骨质疏松症的发生与发展.研究发现,中药可靶向PPARγ调控这些信号通路,促进成骨细胞形成,抑制破骨细胞的吸收作用,从而发挥抗骨质疏松症的作用.本文通过检索PubMed、中国知网、万方、维普等数据库,将近十年收录有关中药通过抑制PPARγ防治骨质疏松症的研究文献进行概括与总结,以期为中药治疗骨质疏松症的深入研究提供参考依据.

Abstract

Osteoporosis is a degenerative disease caused by imbalance between bone absorption and bone formation.Peroxisome proliferation-activated receptors γ(PPARγ)can drive the occurrence and development of OP via Wnt/β-catenin,CEBPα and OPG/RANKL/RANK signal pathways.Research has found that traditional Chinese medicine can target PPAR γ Regulating these signaling pathways,promoting the formation of osteoblasts,inhibiting the absorption of osteoclasts,and thus exerting anti osteoporosis effects.This article indexed databases such as PubMed,CNKI,Wanfang,and VIP,which have included information on how traditional Chinese medicine inhibits PPARγ over the past decade.Summarize and conclude the research literature on the prevention and treatment of osteoporosis,in order to provide reference for in-depth research on traditional Chinese medicine treatment of osteoporosis.

关键词

骨质疏松症/中药/PPARγ/成骨细胞/破骨细胞

Key words

osteoporosis/traditional Chinese medicine/PPARγ/osteoclast/osteoblast

引用本文复制引用

基金项目

陕西省教育厅重点科研项目(23JS006)

陕西省教育厅重点科研项目(20JS029)

陕西中医药大学中医经典理论研究创新团队项目(2019-YL01)

出版年

2024
中国骨质疏松杂志
中国老年学和老年医学学会

中国骨质疏松杂志

CSTPCDCSCD北大核心
影响因子:1.439
ISSN:1006-7108
参考文献量61
段落导航相关论文